ALKS - Alkermes plc.

27.91
0.070   0.251%

Share volume: 1,517,298
Last Updated: 04-28-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$27.84
0.07
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
65%
Profitability 76%
Dept financing 37%
Liquidity 75%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.87%
1 Month
-15.48%
3 Months
-11.57%
6 Months
5.56%
1 Year
12.18%
2 Year
4.83%
Key data
Stock price
$27.91
P/E Ratio 
12.64
DAY RANGE
$27.61 - $28.28
EPS 
$2.22
52 WEEK RANGE
$22.90 - $36.45
52 WEEK CHANGE
$13.73
MARKET CAP 
4.653 B
YIELD 
N/A
SHARES OUTSTANDING 
164.668 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
1.24
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,719,166
AVERAGE 30 VOLUME 
$1,935,753
Company detail
CEO: Richard F. Pops
Region: US
Website: alkermes.com
Employees: 2,280
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Alkermes plc researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL, and VUMERITY. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate.

Recent news
loading